ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1281

Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis

Katharine Moore1,2, Marvin J. Fritzler3, Marisa S. Klein-Gitelman4, Ann M Reed5, Tzielan Lee6 and Anne Stevens7,8, 1Pediatrics, University of Colorado, Aurora, CO, 2Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, 3Medicine, University of Calgary, Calgary, AB, Canada, 4Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, 5Rheumatology, Duke University, Durham, NC, 6Pediatric Rheumatology, Stanford University, Palo Alto, CA, 7University of Washington, Department of Pediatrics, Seattle, WA, 8Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, Juvenile scleroderma, pediatric rheumatology and systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 6, 2017

Session Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile systemic sclerosis (jSSc) is a severe and heterogeneous autoimmune vasculopathy. Pulmonary fibrosis is the highest independent predictor of mortality, yet currently there are no known biomarkers associated with organ involvement, response to therapy, or prognosis in jSSc. CXCL4 is a chemoattractant for neutrophils and fibroblasts. Elevated peripheral levels of CXCL4 have been associated with pulmonary fibrosis, pulmonary hypertension, and overall disease progression in adult SSc. The purpose of this study was to evaluate whether CXCL4 levels are elevated in jSSc patients as compared to healthy pediatric controls and patients with other rheumatologic illnesses, and to determine whether there is an association with jSSc disease manifestations.

Methods: In this multi-center case-control study, plasma samples from 28 patients with jSSc, 26 with localized scleroderma (jLS), 36 with juvenile systemic lupus erythematosus (jSLE), and 35 age-matched healthy controls were tested for CXCL4. Testing was done on a Luminex 200 luminometer (Eve Technologies, Calgary, AB). CXCL4 plasma concentration was compared between diseases and controls. The CXCL4 level was then correlated with specific disease manifestations, including the presence of pulmonary hypertension and pulmonary fibrosis on HRCT.

Results: The mean (± 95% CI) level of CXCL4 in jSSc patients was 24,358 ± 6047 ng per milliliter, which was significantly higher than in controls (12,455 ± 5032 ng/mL; p=.001). Mean CXCL4 in both jLS patients (20,692 ± 4513 ng/mL) and in jSLE (18,165 ± 4360 ng/mL) were also significantly higher than in controls, but to lesser extent (p=.01 and p=.04, respectively). When the Bonferroni correction was applied, only the jSSc cohort was significantly different from controls. There was no significant difference in CXCL4 level between the sub-classifications of jSSc (diffuse versus limited cutaneous SSc). Within the jSSc cohort, there were three patients with PH and a mean CXCL4 level of 41,768 ng/mL (range 3,472 – 79,585), compared to 24,565±19,731 ng/mL for 17 patients with pulmonary fibrosis, and 24,600±8,927 ng/mL for patients without cardiopulmonary involvement.

Conclusion: Levels of plasma CXCL4 were elevated in patients with jSSc and, in a small number of patients, were higher with the presence of pulmonary hypertension. Levels did not correlate with HRCT-confirmed pulmonary fibrosis in this cohort. These findings suggest that CXCL4 may have value as a biomarker in jSSc, but further prospective studies of an inception cohort are needed.


Disclosure: K. Moore, None; M. J. Fritzler, Inova Diagnostics, Inc., 5,Werfen International, 5,Eurimmun GmbH, 5,Alexion Pharmaceuticals, Inc., 5; M. S. Klein-Gitelman, Janssen Pharmaceutica Product, L.P., 2,Pfizer Inc, 2,UCB biosciences, 2,Abbvie, 2,Lupus Foundation of America, 2,NIH/LFA/Cure JM/Arthritis Foundation, 2,Up to Date, 7; A. M. Reed, None; T. Lee, None; A. Stevens, None.

To cite this abstract in AMA style:

Moore K, Fritzler MJ, Klein-Gitelman MS, Reed AM, Lee T, Stevens A. Plasma CXCL4 As a Biomarker in Juvenile Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/plasma-cxcl4-as-a-biomarker-in-juvenile-systemic-sclerosis/. Accessed March 1, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-cxcl4-as-a-biomarker-in-juvenile-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.